Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency

Area of Science:

• Immunology
• Gene Therapy
• Hematology

Background:

• X-linked severe combined immunodeficiency (SCID-X1) results from IL2RG mutations, causing severe T, B, and NK cell deficiencies.
• Previous gamma-retroviral gene therapy in infants restored T cells but not B or NK cells, and failed in older children.
• SCID-X1 patients often have persistent immune dysfunction even after early hematopoietic stem cell transplantation.

Purpose of the Study:

• To evaluate the safety and efficacy of lentiviral gene therapy for SCID-X1 in older patients with prior transplants.
• To assess the restoration of T, NK, and B cell immunity following gene therapy.
• To determine if the treatment improves humoral responses to immunization.

Main Methods:

• Lentiviral vector gene therapy targeting the IL2RG gene was administered to five SCID-X1 patients.
• Treatment involved autologous hematopoietic stem cell (HSC) gene therapy after nonmyeloablative busulfan conditioning.
• Gene marking levels, immune cell populations, and humoral responses were monitored post-treatment.

Main Results:

• In two older patients, gene therapy led to selective expansion of gene-marked T, NK, and B cells.
• Sustained restoration of humoral responses to immunization and clinical improvement were observed at 2-3 years post-treatment.
• Three younger patients showed similar gene marking levels with 6-9 months follow-up.

Conclusions:

• Lentiviral gene therapy with reduced-intensity conditioning is a safe approach for older SCID-X1 patients post-transplant.
• This gene therapy can restore humoral immune function in this patient population.
• The findings suggest a promising therapeutic strategy for persistent immune dysfunction in SCID-X1.